Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors von Italiano, A., Infante, J.R., Shapiro, G.I., Moore, K.N., LoRusso, P.M., Hamilton, E., Cousin, S., Toulmonde, M., Postel-Vinay, S., Tolaney, S., Blackwood, E.M., Mahrus, S., Peale, F.V., Lu, X., Moein, A., Epler, J., DuPree, K., Tagen, M., Murray, E.R., Schutzman, J.L., Lauchle, J.O., Hollebecque, A., Soria, J.-C.

Volltext

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis von Lauchle, Jennifer O., Braun, Benjamin S., Loh, Mignon L., Shannon, Kevin

Volltext

Somatic inactivation of Nfl in hematopoietic cells results in a progressive myeloproliferative disorder von LE, Doan T, NAMIE KONG, SHANNON, Kevin M, YUAN ZHU, LAUCHLE, Jennifer O, AIYIGARI, Abigail, BRAUN, Benjamin S, ENDI WANG, KOGAN, Scott C, LE BEAU, Michelle M, PARADA, Luis

Volltext

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors von Wagner, A. J., Bendell, J. C., Dolly, S., Morgan, J. A., Ware, J. A., Fredrickson, J., Mazina, K. E., Lauchle, J. O., Burris, H. A., De Bono, J. S.

Volltext

Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22 von Curtiss, Nicole P., Bonifas, Jeannette M., Lauchle, Jennifer O., Balkman, Jason D., Kratz, Christian P., Emerling, Brooke M., Green, Eric D., Le Beau, Michelle M., Shannon, Kevin M.

Volltext

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors von Dolly, Saoirse O, Wagner, Andrew J, Bendell, Johanna C, Kindler, Hedy L, Krug, Lee M, Seiwert, Tanguy Y, Zauderer, Marjorie G, Lolkema, Martijn P, Apt, Doris, Yeh, Ru-Fang, Fredrickson, Jill O, Spoerke, Jill M, Koeppen, Hartmut, Ware, Joseph A, Lauchle, Jennifer O, Burris, 3rd, Howard A, de Bono, Johann S

Volltext

Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endo... von Spoerke, Jill M., Makker, Vicky, Aghajanian, Carol, Thomas, Powles, Motzer, Robert J., Lauchle, Jennifer O., Parmar, Hema, Gilbert, Houston, Lin, Wei, O'Keeffe, Bridget, Byrtek, Michelle, Koeppen, Hartmut, Wang, Yulei, Lu, Shan, Huw, Ling-Yuh, Hampton, Garret M., Lackner, Mark R.

Volltext

Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW) von Hollebecque, Antoine, Clamp, Andrew, Horsley, Laura, Morgan, Jeffrey A., Bahleda, Rastilav, George, Suzanne, Shaw, Danielle, Lauchle, Jennifer O., Ware, Joseph, Desai, Rupal, Wu, Jenny, Fu, Ling, Jayson, Gordon C., Soria, Jean-Charles, Wagner, Andrew J.

Volltext